Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Gender-Based Response to Hypomethylating Agents

Leuk Lymphoma; ePub 2016 Oct 24; DeZern, et al

Publish date:: November 9, 2016

There is gender-based response variability to first-line therapy for higher-risk myelodysplastic syndromes, according to a study involving 642 individuals.

Investigators analyzed the influence of gender on overall survival and other outcomes in participants treated with decitabine (DAC) or azacitidine (AZA). Among the results:

Patients treated with DAC had slightly better median overall survival (~19 months) than their AZA-treated counterparts (~16 months); the difference varied substantially by sex.
DAC-treated females had longer median overall survival (~21 months), vs AZA-treated females (~13 months).
Survival was similar in males in both groups (~18 months for both).

Citation:

DeZern A, Zeidan A, Barnard J, et al. Differential response to hypomethylating agents based on sex: A report on behalf of the MDS Clinical Research Consortium. [Published online ahead of print October 24, 2016]. Leuk Lymphoma. doi:10.1080/10428194.2016.1246726.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Multiple Myeloma

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Durable responses with anti-BCMA CAR T-cell for multiple myeloma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,